SCHEMBL29908945

SCHEMBL29908945

CN(C(=O)OC(C)(C)C)c1ccc(NC(=O)CCCCCCC(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 11/20 0.51
HDAC1 Q13547 10/20 0.51
HDAC6 Q9UBN7 10/20 0.51
HDAC3 O15379 9/20 0.51
HDAC2 Q92769 9/20 0.51
HDAC11 Q96DB2 9/20 0.51
HDAC5 Q9UQL6 8/20 0.51
HDAC10 Q969S8 7/20 0.51
HDAC7 Q8WUI4 7/20 0.51
HDAC4 P56524 6/20 0.51
HDAC9 Q9UKV0 6/20 0.51
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 2/20 0.46
NPC1 O15118 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29908940 0.90 HDAC8 (0.56) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL29908939 0.83 HDAC8 (0.47) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL1066363 0.82 HDAC8 (0.57) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL7109424 0.78 ALDH1A1 (0.59) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL7828619 0.78 ALDH1A1 (0.59) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL29245786 0.77 PAX8 (0.43) ALDH1A1MAPTNPC1ALOX15MAPK1
SCHEMBL3460830 0.77 RAB9A (0.54) ALDH1A1MAPTNPC1NFKB1MAPK1
Sebacic Acid SCHEMBL3905690 0.77 HDAC8 (0.57) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL7813937 0.76 MAPT (0.69) HDAC8HDAC1HDAC6HDAC3HDAC2
SCHEMBL1163445 0.76 CA1 (0.54) HDAC8HDAC1HDAC3HDAC2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4054607-A1 SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2022-09-14 EP disclosed